Redirecting Tryptophan Metabolism Through Host‐Microbial Crosstalk to Enhance Precise Bioorthogonal Chemoimmunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.202517934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Yue Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy…. Hauptthemen laut MEDLINE: Tryptophan, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Bioorthogonal chemistry offers a promising approach for advancing chemoimmunotherapy, yet two critical challenges remain: (1) achieving deep tumor penetration of catalysts while ensuring precise tumor‐confined prodrug activation, and (2) reversing metabolic immunosuppression to potentiate immunotherapy efficacy. To tackle these issues, here we fabricate a bioorthogonal probiotic nanosystem (NP@ZIF‐8@Apt‐Lr) by engineering prodrug catalysts and an indoleamine 2,3‐dioxygenase (IDO) inhibitor onto AS1411 aptamer‐modified Lactobacillus reuteri (Lr). AS1411‐guided recognition and GSH‐responsive prodrug decaging provide a double guarantee for tumor‐selective drug activation, enabling localized tumor killing and further immunogenic cell death (ICD). Also, the inherent tumor‐homing properties of Lr endow the nanosystem with the ability of penetrating deep tissue. More crucially, the released IDO inhibitor blocks the immunosuppressive kynurenine pathway of tryptophan metabolism, while Lr redirects tryptophan metabolism toward the immunostimulatory indole‐3‐aldehyde pathway through host‐microbial crosstalk. Upon treatment, NP@ZIF‐8@Apt‐Lr overcomes immune tolerance and stimulates T lymphocyte infiltration into tumors. Furthermore, it significantly enhances the efficacy of chemoimmunotherapy by suppressing bilateral tumor development and inducing an immune memory response. This work presents a new strategy for enhancing bioorthogonal chemoimmunotherapy through precise prodrug activation and probiotic‐mediated metabolic reprogramming by host‐microbial crosstalk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Chemical Biology and State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, P. R. China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, Anhui, P. R. China.
ORCID-Profile: Xiaogang Qu
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Sun, Y., Huang, C., Ma, C., Zhao, C., Liu, M., Zhu, Z., Zhang, Y., Ren, J., & Qu, X. (2026). Redirecting Tryptophan Metabolism Through Host‐Microbial Crosstalk to Enhance Precise Bioorthogonal Chemoimmunotherapy. Advanced Materials. https://doi.org/10.1002/adma.202517934
Vancouver
Sun Y, Huang C, Ma C, Zhao C, Liu M, Zhu Z, et al. Redirecting Tryptophan Metabolism Through Host‐Microbial Crosstalk to Enhance Precise Bioorthogonal Chemoimmunotherapy. Advanced Materials. 2026. doi:10.1002/adma.202517934
BibTeX
@article{Sun2026,
author = {Sun, Yue and Huang, Congcong and Ma, Chenglong and Zhao, Chuanqi and Liu, Mengmeng and Zhu, Zitong and Zhang, Yanjie and Ren, Jinsong and Qu, Xiaogang},
title = {Redirecting Tryptophan Metabolism Through Host‐Microbial Crosstalk to Enhance Precise Bioorthogonal Chemoimmunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202517934}
}
EUVIMED